Semaglutide Shows Weight Loss-Independent Benefits for Osteoarthritis and Other Health Conditions

A recent study published in Cell Metabolism on February 9 indicates that GLP-1 receptor agonist drugs, such as semaglutide, may offer health benefits beyond weight loss, particularly for conditions like osteoarthritis. Research conducted in animal models and a small human trial suggests that semaglutide can facilitate cartilage restoration and improve various health markers through direct cellular mechanisms, independent of its effects on body weight.

Osteoarthritis Progression and Semaglutide's Impact

Medical researchers identified that semaglutide, a drug known for its use in treating type 2 diabetes and supporting weight loss, may influence tissue damage associated with osteoarthritis, the most common form of arthritis. The drug demonstrated joint protection in mice through a mechanism independent of weight reduction.

Semaglutide was observed to reprogram the metabolism of chondrocytes, the cells responsible for synthesizing and maintaining cartilage. This reprogramming shifts their energy generation from glycolysis, a less efficient pathway, toward oxidative phosphorylation (OXPHOS), a more efficient, oxygen-dependent process.

Specifically, in osteoarthritis-affected mice, chondrocytes primarily utilized glycolysis, producing two ATP molecules per glucose. Following semaglutide treatments, OXPHOS, capable of producing up to 36 ATP molecules per glucose, became the preferred metabolic pathway. This metabolic modification is attributed to the drug's influence on the "GLP-1R-AMPK-PFKFB3 axis," a cascade affecting cellular energy production.

In both mice and humans with obesity and osteoarthritis, semaglutide treatment led to reduced pain and decreased cartilage degeneration. Mouse experiments also showed fewer bone spurs and less severe lesions in joint membranes.

A control group of "pair-fed" mice, which experienced comparable weight changes without semaglutide, did not exhibit the same cartilage protection, indicating a direct, weight loss-independent effect on the joint.

Broader Health Implications

Beyond osteoarthritis, the study's findings suggest additional weight loss-independent benefits for semaglutide in other health areas:

• Heart Outcomes: Approximately 66% of the reduction in major adverse cardiovascular events (MACE) was observed to be unrelated to weight loss, with arterial inflammation reportedly reducing immediately.
• Kidney Health: A 100% effect on kidney outcomes was found to be independent of weight loss, involving direct interaction with GLP-1 receptors in the kidney and reduced protein excretion.
• Liver Health: For metabolic dysfunction-associated steatohepatitis (MASH), 50-70% of the benefit was unrelated to weight loss, including reduced lipotoxicity and improved liver enzymes observed before any weight loss occurred.

These findings suggest a broader potential application for semaglutide beyond metabolic diseases, extending to joint degenerative conditions and other health issues.

Human Trial Details and Future Outlook

The research included a randomized human trial involving 20 individuals aged 50-75 diagnosed with both obesity and osteoarthritis. Participants were randomized into two groups: one received sodium hyaluronate (HA), and the other received HA plus semaglutide. After 24 weeks, the HA+semaglutide group reported lower osteoarthritis pain scores and improvements in knee function. MRI analysis also indicated thicker cartilage and evidence of cartilage growth in the inner weight-bearing areas of the knee joint.

Osteoarthritis affects approximately 600 million people globally and is projected to impact one billion by 2050, with an increasing prevalence in younger populations. Current osteoarthritis therapies are primarily palliative, focusing on symptom management.

While the work contributes to evidence of GLP-1 drugs having benefits beyond weight loss, it is noted that findings from mouse studies do not always translate to long-term human outcomes, and semaglutide use has associated side effects. Researchers concluded that the protective effects observed on the human knee joint require further validation through additional clinical trials.